GSK-690693

• CAT Number: I005569
• CAS Number: 937174-76-0
• Molecular Formula: C₂₁H₂₇N₇O₃
• Molecular Weight: 425.48
• Purity: ≥95%
• Synonyms: GSK690693;GSK 690693
• Target: Epigenetics
• Solubility: DMSO ≥36mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL
• Storage: 2-8°C
• IC50: 2 nM/13 nM/9 nM(Akt1/2/3)
• IUPAC Name: 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[[(3S)-piperidin-3-yl]methoxy]imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol
• InChI: InChI=1S/C21H27N7O3/c1-4-28-18-15(30-12-13-6-5-9-23-10-13)11-24-14(7-8-21(2,3)29)16(18)25-20(28)17-19(22)27-31-26-17/h11,13,23,29H,4-6,9-10,12H2,1-3H3,(H2,22,27)/t13-/m0/s1
• InChIKey: KGPGFQWBCSZGEL-ZDUSSCGKSA-N
• SMILES: CCN1C2=C(C(=NC=C2OCC3CCCNC3)C#CC(C)(C)O)N=C1C4=NON=C4N

GSK-690693（Cat No.:I005569）, is a potent and selective inhibitor of AKT (protein kinase B). It functions by targeting and inhibiting all three isoforms of AKT (AKT1, AKT2, and AKT3). GSK-690693 has demonstrated anticancer activity by blocking the signaling pathways involved in cell survival and proliferation. It has been investigated as a potential therapeutic agent in various cancer types, including leukemia, breast cancer, and lung cancer. GSK-690693 shows promise in the development of targeted therapies against AKT-driven malignancies.

Reference

[1]. Rhodes N, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res, 2008, 68(7), 2366-2374. 


[2]. Levy DS, et al. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood, 2009, 113(8), 1723-1729. 


[3]. Altomare DA, et al. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res, 2010, 16(2), 486-496.